JP5943996B2 - 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 - Google Patents

腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 Download PDF

Info

Publication number
JP5943996B2
JP5943996B2 JP2014513035A JP2014513035A JP5943996B2 JP 5943996 B2 JP5943996 B2 JP 5943996B2 JP 2014513035 A JP2014513035 A JP 2014513035A JP 2014513035 A JP2014513035 A JP 2014513035A JP 5943996 B2 JP5943996 B2 JP 5943996B2
Authority
JP
Japan
Prior art keywords
sequence
gene expression
expression cassette
gfp
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014513035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523236A5 (https=
JP2014523236A (ja
Inventor
王▲尭▼河
姜国忠
黄▲漢▼熙
曹▲風▼雨
莱蒙・尼克
Original Assignee
北京▲錘▼特生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京▲錘▼特生物科技有限公司 filed Critical 北京▲錘▼特生物科技有限公司
Publication of JP2014523236A publication Critical patent/JP2014523236A/ja
Publication of JP2014523236A5 publication Critical patent/JP2014523236A5/ja
Application granted granted Critical
Publication of JP5943996B2 publication Critical patent/JP5943996B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014513035A 2011-05-31 2012-02-29 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 Active JP5943996B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011101433853A CN102260712B (zh) 2011-05-31 2011-05-31 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
CN201110143385.3 2011-05-31
PCT/CN2012/071757 WO2012163119A1 (zh) 2011-05-31 2012-02-29 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用

Publications (3)

Publication Number Publication Date
JP2014523236A JP2014523236A (ja) 2014-09-11
JP2014523236A5 JP2014523236A5 (https=) 2015-08-20
JP5943996B2 true JP5943996B2 (ja) 2016-07-05

Family

ID=45007547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513035A Active JP5943996B2 (ja) 2011-05-31 2012-02-29 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用

Country Status (5)

Country Link
US (3) US9315827B2 (https=)
EP (1) EP2716764B1 (https=)
JP (1) JP5943996B2 (https=)
CN (1) CN102260712B (https=)
WO (1) WO2012163119A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN106591368A (zh) * 2016-10-12 2017-04-26 郑州大学 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN110093323B (zh) * 2018-01-31 2024-01-30 上海元宋生物技术有限公司 重组溶瘤腺病毒OncoAd-P28GANK-E1A-△E1B及其构建方法和应用
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372823T3 (es) * 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
AP2351A (en) * 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
CN102220357B (zh) * 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用

Also Published As

Publication number Publication date
US20160222413A1 (en) 2016-08-04
US20180187214A1 (en) 2018-07-05
CN102260712B (zh) 2013-10-02
US9932606B2 (en) 2018-04-03
EP2716764A1 (en) 2014-04-09
US20140088180A1 (en) 2014-03-27
EP2716764A4 (en) 2015-01-14
US10294493B2 (en) 2019-05-21
US9315827B2 (en) 2016-04-19
CN102260712A (zh) 2011-11-30
WO2012163119A1 (zh) 2012-12-06
EP2716764B1 (en) 2019-05-01
JP2014523236A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
JP5943996B2 (ja) 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用
JP2014523236A5 (https=)
JP6817979B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
EP2137301B1 (en) Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment.
CN103614416B (zh) 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
Yan et al. Developing novel oncolytic adenoviruses through bioselection
AU2002346084B2 (en) Viral mutants that selectively replicate in targeted human cancer cells
Wang et al. Adenovirus vector-mediated single chain variable fragments target the nucleocapsid protein of porcine epidemic diarrhea virus and protect against viral infection in piglets
WO2022192278A2 (en) Muc16 promoter containing virus
AU2024297471A1 (en) Adenoviruses
CN117247910A (zh) 重组溶瘤痘苗病毒及其应用
AU2024287471A1 (en) Mutated adenoviruses with improved replication and their use for treating cancer
WO2025133561A1 (en) Adenoviruses
Stepanenko et al. Potency-enhancing mutations in E3-19K and i-Leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5-Δ24-RGD
Lobby Factors Impacting the Generation and Maintenance of CD8+ Tissue-Resident Memory T Cells Following Respiratory Immunization
WO2024251286A1 (zh) 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用
Kong Determining the oncogenic activity of different Epstein-Barr virus proteins on the development of nasopharyngeal cancer
CN120738288A (zh) 重组腺病毒载体和基于该载体的复制型腺病毒重组体及其构建方法
Young A Development of an immunocompetent model of oncolytic adenoviral gene therapy for ovarian cancer.
Hammer Engineering of oncolytic adenoviruses for delivery by mesenchymal stem cells to pancreatic cancer

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150519

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160524

R150 Certificate of patent or registration of utility model

Ref document number: 5943996

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250